您当前所在的位置:首页 > 产品中心 > 产品信息
KR-62436 hydrate_分子结构_CAS_761414-79-3(freebase))
点击图片或这里关闭

KR-62436 hydrate

产品号 K4264 公司名称 Sigma Aldrich
CAS号 761414-79-3(freebase) 公司网站 http://www.sigmaaldrich.com
分子式 C14H19Cl2N7O2 电 话 1-800-521-8956
分子量 388.25236 传 真
纯 度 ≥98% (HPLC) 电子邮件
保 存 Chembase数据库ID: 153941

产品价格信息

请登录

产品别名

标题
KR-62436 hydrate
IUPAC标准名
6-[(2-{[2-(5-cyano-4,5-dihydro-1H-pyrazol-1-yl)-2-oxoethyl]amino}ethyl)amino]pyridine-3-carbonitrile hydrate dihydrochloride
IUPAC传统名
6-[(2-{[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethyl]amino}ethyl)amino]pyridine-3-carbonitrile hydrate dihydrochloride
别名
6-{2-[(5-Cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino}nicotinonitrile dihydrochloride hydrate

产品登记号

CAS号 761414-79-3(freebase)
MDL号 MFCD17215675
PubChem SID 24724521

产品性质

Empirical Formula (Hill Notation) C14H15N7O·2HCl · xH2O
纯度 ≥98% (HPLC)
外观 light tan solid
溶解度 DMSO: >10 mg/mL
溶解度 H2O: >5 mg/mL
GHS危险品标识 GHS07
GHS警示词 Warning
GHS危险声明 H302
欧盟危险性物质标志 有害性(Harmful) 有害性(Harmful) (Xn)
MSDS下载 下载链接
个人保护装置 dust mask type N95 (US), Eyeshields, Faceshields, Gloves
危险公开号 22
保存温度 2-8°C
德国WGK号 3

产品详细信息

详细说明 (English)
Biochem/physiol Actions
KR-62436 is a competitive inhibitor of dipeptidyl peptidase-IV (DPP-IV). DPP-IV is a serine protease which inactivates glucagon-like peptide (GLP-1); IC50 0.1-0.8 μM; GLP-1 is a potent stimulus for insulin secretion and inducer of satiety after food intake, but it has a very short action (1 min) because it is rapidly degraded by DPP-IV; blocking DPP-IV increases GLP-1 action and increases plasma insulin levels; DPP-IV inhibitors and KR-62436 have clinical potential as anti-diabetic agents
详细说明 (简体中文)
Biochem/physiol Actions
KR-62436 is a competitive inhibitor of dipeptidyl peptidase-IV (DPP-IV). DPP-IV is a serine protease which inactivates glucagon-like peptide (GLP-1); IC50 0.1-0.8 μM; GLP-1 is a potent stimulus for insulin secretion and inducer of satiety after food intake, but it has a very short action (1 min) because it is rapidly degraded by DPP-IV; blocking DPP-IV increases GLP-1 action and increases plasma insulin levels; DPP-IV inhibitors and KR-62436 have clinical potential as anti-diabetic agents

参考文献